anxiety
Anxiety disorders β€” including generalized anxiety disorder (GAD), social anxiety disorder, PTSD, panic disorder, and OCD β€” collectively represent the most prevalent psychiatric condition globally, affecting approximately 30% of adults at some point in their lives. Despite widespread availability of SSRIs, SNRIs, and benzodiazepines, substantial proportions of patients fail to achieve remission, driving an active clinical trial landscape for novel mechanisms and delivery formats.
Active trials investigate CRHR1 antagonists for stress-induced anxiety, V1b vasopressin receptor antagonists, cannabidiol formulations, MDMA-assisted psychotherapy for PTSD (Phase 3 results showed strong efficacy in two trials), ketamine infusion for severe GAD refractory to other treatments, transcranial magnetic stimulation (TMS), and digital therapeutics combining cognitive behavioral therapy with biometric monitoring. PTSD trials often recruit veterans and first responders.
Anxiety trials typically use validated rating scales (HAM-A, GADARS, CAPS-5 for PTSD) at baseline and follow-up; prior SSRIs/SNRIs trials and current benzodiazepine use are common eligibility considerations.
Disease Burden & Epidemiology
Anxiety disorders are the most prevalent category of mental health conditions globally. The World Health Organization estimates that 301 million people worldwide had an anxiety disorder in 2019 — before the COVID-19 pandemic, which caused an estimated 26% increase in prevalence in the first year alone. In the United States, the National Institute of Mental Health reports that 31.1% of adults will experience an anxiety disorder at some point in their lives, making it the most common mental health condition in the country. Generalized anxiety disorder (GAD) affects approximately 6.8 million US adults; PTSD affects 12 million; social anxiety disorder affects 15 million; panic disorder affects 6 million; and OCD affects 2.3 million. Women are twice as likely as men to be affected by most anxiety disorder subtypes. Economically, anxiety disorders cost the US approximately $47 billion annually in direct treatment costs and productivity losses. Despite availability of first-line SSRIs and SNRIs, remission rates are disappointingly low — approximately 40–60% of patients fail to achieve full remission with initial pharmacotherapy, and relapse rates upon discontinuation are high. This treatment gap sustains a large and active clinical trial pipeline targeting novel neurobiological mechanisms.
Key Research Trends & Landmark Studies
The most consequential recent trials in the anxiety space involve MDMA-assisted psychotherapy for PTSD. The MAPP1 and MAPP2 Phase 3 trials, conducted by MAPS Public Benefit Corporation, showed that MDMA combined with psychotherapy produced a 67–71% response rate and 46–67% remission rate in chronic PTSD — results that were substantially superior to any prior pharmacological intervention for PTSD. Although FDA approval was not granted in the initial 2024 review due to trial design concerns, MAPS is pursuing approval with an additional trial. For GAD, the Phase 2 trial of PH10 (intranasal neurosteroid) and multiple programs targeting V1b vasopressin receptors (ABT-558) have advanced on the back of prior positive signals. In OCD, the TACTIC trial established deep TMS as an effective neuromodulation approach, achieving FDA clearance and enabling broader access. The STAR*D-PTSD follow-up programs and multiple VA-sponsored trials continue to generate effectiveness data in veteran and military populations with combat-related PTSD.
Patient Guide: How to Find & Join a Trial
Adults with an anxiety disorder diagnosis — confirmed by a mental health professional using DSM-5 criteria — are broadly eligible for many anxiety clinical trials. The specific disorder subtype (GAD, PTSD, social anxiety, panic, OCD) determines which trials are relevant, as these are treated as distinct conditions in trial design. For PTSD trials specifically, a formal CAPS-5 assessment by a trained clinician is typically required at screening — this is a structured interview lasting 45–60 minutes that quantifies PTSD severity. Veterans and first responders with PTSD should specifically contact the nearest VA Medical Center's mental health research program, as VA and DoD fund extensive PTSD trial networks with streamlined enrollment for this population. For GAD and social anxiety trials, academic psychiatry departments and specialty anxiety clinics associated with university hospitals offer the broadest portfolios. Many current anxiety trials offer remote or hybrid participation formats, particularly for behavioral intervention arms.